A Study To Evaluate Escalating Doses of A Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC

By enrolling patients with advanced NSCLC and metastatic TNBC according to the enrollment
criteria, this study will evaluate the first-in-patient safety, PK, PD and early signs of
efficacy of the vaccine-based immunotherapy regimen.

Inclusion Criteria: -Histological or cytological diagnosis of non-small cell lung cancer or
triple-negative breast cancer

-Adequate bone marrow, kidney, and liver function

Exclusion Criteria:

- ECOG performance status greater than or equal to 2

- concurrent immunotherapy

- History of or active autoimmune disorders (including but not limited to: myasthenia
gravis, thyroiditis, pneumonitis, rheumatoid arthritis, multiple sclerosis, systemic
lupus, erythematosus, scleroderma) and other conditions that disorganize or alter the
immune system.

- History of inflammatory bowel disease.

- Current use of any implanted electronic stimulation device, such as cardiac demand
pacemakers, automatic implantable cardiac defibrillator, nerve stimulators, or deep
brain stimulators.

- Presence of any surgical or traumatic metal implants at the site of administration